BBLG VS GLMD Stock Comparison

Performance

BBLG
10/100

BBLG returned -94.35% in the last 12 months. Based on SPY's performance of 9.73%, its performance is below average giving it a score of 10 of 100.

GLMD
10/100

GLMD returned -92.16% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Technicals

BBLG
14/100

BBLG receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

GLMD
43/100

GLMD receives a 42 of 100 based on 14 indicators. 5 are bullish, 7 are bearish.

Earnings

BBLG
49/100

BBLG has missed earnings 2 times in the last 20 quarters.

GLMD
10/100

GLMD has missed earnings 6 times in the last 20 quarters.

Profit

BBLG
10/100

Out of the last 20 quarters, BBLG has had 1 profitable quarters and has increased their profits year over year on 1 of them.

GLMD
10/100

Out of the last 20 quarters, GLMD has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

BBLG
46/100

BBLG has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.

GLMD
44/100

GLMD has had a lower than average amount of volatility over the last 12 months giving it a score of 43 of 100.

Analyst Price Targets

BBLG

"Analyst Price Targets" not found for BBLG

GLMD
75/100

5 analysts offer 12-month price targets for GLMD. Together, they have an average target of 0, the most optimistic target put GLMD at 0 within 12-months and the most pessimistic has GLMD at 0.

All score calculations are broken down here to help you make more informed investing decisions

Bone Biologics Corp Common Stock Summary

Nasdaq / BBLG

Healthcare

Medical - Devices

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.

Galmed Pharmaceuticals Ltd. Summary

Nasdaq / GLMD

Healthcare

Biotechnology

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

Power up your portfolio